On June 19, Gufic Biosciences gained 5% to its 52-week high of Rs 245 in the early morning trade after its anaesthesia drug API acknowledged the green signal from China’s National Medical Products Administration (NMPA).

Gufic Biosciences Limited (Gufic) have got consent from the National Medical Products Administration (NMPA), China, for its product Prilocaine (API) which is an amide-type local anaesthetic of fast onset and intermediate period of action. This approval will benefit it in selling the product in Chinese bazaars.

Prilocaine has a medical profile similar to lidocaine and is used for infiltration, peripheral nerve blocks, and spinal and epidural anaesthesia. Also, in amalgamation with lidocaine, it is used for surface anaesthesia.

Prilocaine offers a meaningfully larger duration and safety margin without a vasopressor. Hence, the accumulation of epinephrine is not obligatory to lengthen the duration of action, which can be a benefit when epinephrine is contraindicated.
At 9:25 am, Gufic Biosciences was trading at Rs 239.00, up Rs 6.45, or 2.77%, on the BSE.